Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina

Autor:	G Streger, C. Caprarulo, A Babini, E. Velozo, S Perez Rodriguez, S Magri, A.M. Cappuccio, Mireia García, G Casado, H Figueredo, B A Pons-Estel, M Iglesias-Rodriguez, Alicia Eimon, P Mannucci
Rok vydání:	2020
Předmět:	Adult Male medicine.medical_specialty real-world Clinical effectiveness Argentina steroid sparing Antibodies Monoclonal Humanized Severity of Illness Index Disease activity 03 medical and health sciences 0302 clinical medicine Rheumatology systemic lupus erythematosus Adrenal Cortex Hormones Steroid sparing Internal medicine medicine Humans Lupus Erythematosus Systemic In patient 030212 general & internal medicine skin and connective tissue diseases Retrospective Studies 030203 arthritis & rheumatology business.industry Middle Aged Belimumab Clinical Practice Treatment Outcome Papers Observational study Drug Therapy Combination Female observational study business disease activity Immunosuppressive Agents medicine.drug
Zdroj:	Lupus
ISSN:	1477-0962
Popis:	Objective To describe clinical effectiveness of belimumab for systemic lupus erythematosus (SLE) in real-world practice in Argentina. Methods This retrospective, observational study analysed medical record data of patients with SLE treated with belimumab in 15 centres in Argentina. Primary endpoint: overall clinical response (assessed on a scale similar to the 6-point Physician Global Assessment) at months 6, 12, 18 and 24, all versus index (belimumab initiation). Secondary endpoints: improvement in disease activity (SELENA-SLEDAI), SLE manifestations, and corticosteroid dose change. Results Records for 81 patients (91% female) were analysed. Clinical improvements were reported for 95%, 95%, 98% and 100% patients at 6, 12, 18, and 24 months post index, respectively. Mean SELENA-SLEDAI score decreased from 11.21 at index to 4.76, 3.77, 3.86 and 2.17 at 6, 12, 18, and 24 months post index, respectively. Number of flares decreased from 1.05 at index to 0.21, 0.09, 0.22 and 0.30 at 6, 12, 18, and 24 months post index, respectively. Mean corticosteroid dose was 14.59 mg/day at index, and 6.45, 5.18, 5.17 and 4.78 mg/day at 6, 12, 18, and 24 months post index, respectively. Conclusions Real-world patients with SLE treated with belimumab in Argentina demonstrated clinical improvements and reductions in corticosteroid dose.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eff9b825616822ffec63e94a29297fc6 https://pubmed.ncbi.nlm.nih.gov/32791930 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.